A. As used in this section:

(1)     “340B drug” means a drug that is purchased at a discount in accordance with the 340B program requirements;

(2)     “340B program” means the federal drug pricing program created pursuant to 42 U.S.C. § 256b;

(3)     “covered entity” means an entity participating in the 340B program; and

(4)     “pharmacy benefits manager” means an entity that provides pharmacy benefits management services.

B. A pharmacy benefits manager or a third party shall not discriminate against a covered entity on the basis of its participation in the 340B program by:

(1)     reimbursing a covered entity for a 340B drug at a rate lower than that paid for the same drug to pharmacies, similar in prescription volume, that are non-covered entities;

(2)     assessing a fee, chargeback or other adjustment to the covered entity that is not assessed to non-covered entities;

(3)     imposing a provision that prevents or interferes with a person’s choice to receive 340B drugs from a covered entity; or

(4)     imposing terms or conditions that differ from terms or conditions imposed on a non-covered entity, including:

(a) restricting or requiring participation in a pharmacy network;

(b) requiring more frequent auditing or a broader scope of audit for inventory management systems using generally accepted accounting principles;

(c) requiring a covered entity to reverse, resubmit or clarify a claim after the initial adjudication, unless these actions are in the normal course of pharmacy business and not related to the 340B program; or

(d) charging an additional fee or provision that prevents or interferes with an individual’s choice to receive a 340B drug from a covered entity.